{"entity":{"id":"fusion-pharma","kind":"company","name":"Fusion Pharmaceuticals (AstraZeneca)","aka":[],"tldr":"Alpha-emitter company acquired by AstraZeneca ($2.4B, 2024); FPI-2265 (225Ac-PSMA-I&T) in phase 3.","summary":"Fusion Pharmaceuticals, based in Hamilton, Ontario, is the alpha-emitter company acquired by AstraZeneca for 2.4 billion dollars in 2024, and its FPI-2265, an actinium-225 PSMA-I&T agent, is in phase 3. Its pipeline also includes FPI-2068, an EGFR by c-MET bispecific radioconjugate, and the company holds actinium-225 supply agreements. OnCo links it to the AlphaBreak trial of FPI-2265 and the AcTION trial of 225Ac-PSMA-617, to targeted alpha therapy, to the actinium-225 PSMA agents record and to the radiopharmaceutical roadmap. Whether actinium PSMA therapy can improve on lutetium PSMA therapy is the question AlphaBreak will answer. Actinium-225 PSMA agents have their own page.","asOf":"2026-09-04","links":[{"label":"Official website","url":"https://www.astrazeneca.com"}],"tags":[],"related":[],"cancers":[],"sections":["radiopharma"],"technologies":[],"targets":[],"drugs":["ac225-psma"],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"hq":"Hamilton, ON","country":"CA","companyType":"radiopharma","website":"https://www.astrazeneca.com","investors":[],"funding":[]},"route":"/companies/fusion-pharma/","neighbours":{"section":[{"id":"radiopharma","kind":"section","name":"Radiopharmaceuticals & Theranostics","route":"/fronts/radiopharma/"}],"drug":[{"id":"ac225-psma","kind":"drug","name":"Actinium-225 PSMA agents","route":"/drugs/ac225-psma/"}],"trial":[{"id":"alphabreak","kind":"trial","name":"AlphaBreak (FPI-2265) & AcTION (225Ac-PSMA-617)","route":"/trials/alphabreak/"}],"technology":[{"id":"targeted-alpha-therapy","kind":"technology","name":"Targeted alpha therapy","route":"/technologies/targeted-alpha-therapy/"}],"roadmap":[{"id":"radiopharma-roadmap","kind":"roadmap","name":"Radiopharmaceutical roadmap: iodine → lutetium → actinium","route":"/roadmaps/radiopharma-roadmap/"}]}}